Cargando…
Efficacy and safety of colistin in the treatment of infections in the ICU caused by multidrug-resistant Gram-negative organisms
Autores principales: | Pavleas, J, Skiada, A, Rigas, K, Salatas, K, Belivanakis, G, Archodoulis, N, Mega, A, Vernikos, P, Thomopoulos, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092475/ http://dx.doi.org/10.1186/cc4447 |
Ejemplares similares
-
Trends of resistance of Gram-negative bacteria in the ICU during a 3-year period
por: Skiada, A, et al.
Publicado: (2008) -
The use of recombinant factor VIIa as a haemostatic agent in ICU patients
por: Vernikos, P, et al.
Publicado: (2004) -
Efficacy and safety of once daily dosing of colistin to critically ill patients
por: Skiada, A, et al.
Publicado: (2010) -
Colistin monotherapy versus combination of colistin with a β-lactam or rifampicin for the treatment of serious infections in the ICU due to multidrug-resistant Gram-negative bacteria
por: Tsimogianni, A, et al.
Publicado: (2006) -
Parenteral colistin for the treatment of severe infections by multidrug-resistant Gram-negative bacteria
por: Grion, C, et al.
Publicado: (2013)